Serum Proteomic Profiling Can Discriminate Prostate Cancer From Benign Prostates in Men With Total Prostate Specific Antigen Levels Between 2.5 and 15.0 Ng/Ml

Ornstein, David K.; Rayford, Walter; Fusaro, Vincent A.; Conrads, Thomas P.; Ross, Sally; Hitt, Ben A.; Wiggins, Wesley W.; Veenstra, Timothy D.; Liotta, Lance A.; Petricoin, Emanuel F.

doi:10.1097/01.ju.0000139572.88463.39

Cited by 113 publications

(61 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, the reproducibility of SELDI-TOF MS approaches have been questioned [64][65][66][67]. Nevertheless, interesting results have been obtained by the evaluation of SELDI-TOF MS patterns of the serum of patients with total prostate specific antigen levels between 2.5 and 15.0 ng/mL, presenting either with prostate cancer or with benign prostate pathologies [68]. Using artificial intelligence based on pattern recognition algorithms, it was possible to find patterns distinguishing these two categories of patients.…”

Section: Clinical Applications -Biomarker Identificationmentioning

confidence: 99%

Recent advances in blood‐related proteomics

et al. 2005

View full text Add to dashboard Cite

Service régional vaudois de transfusion sanguine, Lausanne, SwitzerlandBlood is divided in two compartments, namely, plasma and cells. The latter contain red blood cells, leukocytes, and platelets. From a descriptive medical discipline, hematology has evolved towards a pioneering discipline where molecular biology has permitted the development of prognostic and diagnostic indicators for disease. The recent advance in MS and protein separation now allows similar progress in the analysis of proteins. Proteomics offers great promise for the study of proteins in plasma/serum, indeed a number of proteomics databases for plasma/ serum have been established. This is a very complex body fluid containing lipids, carbohydrates, amino acids, vitamins, nucleic acids, hormones, and proteins. About 1500 different proteins have recently been identified, and a number of potential new markers of diseases have been characterized. Here, examples of the enormous promise of plasma/serum proteomic analysis for diagnostic/prognostic markers and information on disease mechanism are given. Within the blood are also a large number of different blood cell types that potentially hold similar information. Proteomics of red blood cells, until now, has not improved our knowledge of these cells, in contrast to the major progresses achieved while studying platelets and leukocytes. In the future, proteomics will change several aspects of hematology.

show abstract

Section: Clinical Applications -Biomarker Identificationmentioning

confidence: 99%

Recent advances in blood‐related proteomics

et al. 2005

View full text Add to dashboard Cite

show abstract

“…More than 3,000 different VOCs have been observed in normal human breath [9], all of them with low molecular weights (<600), unlike protein serum tumor markers which have molecular weights of several kilodaltons [15,16]. Induced cytochrome p450 mixed oxidase activity could potentially modulate the catabolism of many of these breath VOCs, and thereby account for the large and diverse sets of candidate breath biomarkers associated with lung cancer.…”

Section: Biological Significance and Variationmentioning

confidence: 99%

Detection of lung cancer using weighted digital analysis of breath biomarkers

Phillips

Altorki

Austin

et al. 2008

Clinica Chimica Acta

201

168

View full text Add to dashboard Cite

show abstract

“…Protein expression patterns may identify not only proteins with potentially pivotal roles in oncogenesis but also accurate biomarkers of a patient's outcome. 8,9 In the field of hematology, evidence that leukemia FAB (French American British) subtypes, 10 cytogenetic risk groups 11 and hematopoietic stem cell-like fractions 12 are associated with specific proteomes has already been published. The interest and importance of proteomics in the research of prognostic markers was revealed for AML, 13,14 clinical behavior predictions in adult acute lymphoblastic leukemia 15 and therapy-related proteome variations.…”

Section: Introductionmentioning

confidence: 99%